1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Flexion's OA Knee Injection On Track For H2 Filing

 
• By John Davis

Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.

Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.